Keywords: Sanofi, Regeneron, Zaltrap, Colorectal cancer, Ph III, USA, FDA priority review

Sanofi and Regeneron mCRC drug Zaltrap misses goals but gets FDA priority

Article | 10 April 2012

• Print This

The US Food and Drug Administration has granted priority review of the Biologics License Application (BLA) for the investigational agent ...

Enjoying this article? To continue reading you need to login or subscribe.